|From: CASHRICHFIELD (Rep: 47)||Date: 05/23/2020 14:45|
|Forum: Wall Street Pit - Msg #2848945 - List BLPH msgs ||Thread #674159491 (Rec: 0) |
|INOPULSE® is In FDA approved Phase 3 Trials and has partnered with manufacturer Flextronics.International Ltd to provide the Mark2 version of these devices to healthcare professionals. |
Brookline Capital says CV19 opportunities creates $250 mil for Bellephoron which is a lucrative revenue stream for a company with a market cap under $100 mil.
Traders once owned this stock but a recent offering has bought in a fresh group of investors who are long the stock.
Consensus analyst have a $30 target for shares of BLPH which is a 101.75% premium over the recent close @ $14.87/shr.
Sent from my IPhone
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.